Alnylam Pharmaceuticals $ALNY announced that the Data Monitoring Committee (DMC) for its Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7 and recommended continuation of the study without alteration. The APOLLO DMC met at the request of the Company following the decision announced on October 5 to suspend development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). The DMC will continue to meet intermittently per their remit to monitor the overall safety of patisiran in APOLLO through its completion. The topine data is expected in mid-2017.